Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification

Richard M Deans,David W. Morgens,Ayse Okesli,Sirika Pillay,Max A. Horlbeck,Martin Kampmann,Luke A. Gilbert,Amy Li,Roberto Mateo,Mark Smith,Jeffrey S. Glenn,Jan E. Carette,Chaitan Khosla,Michael C. Bassik

Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification

2016

Richard M Deans
David W. Morgens
Ayse Okesli
Sirika Pillay
Max A. Horlbeck
Martin Kampmann
Luke A. Gilbert
Amy Li
Roberto Mateo
Mark Smith
Jeffrey S. Glenn
Jan E. Carette
Chaitan Khosla
Michael C. Bassik

A combination of shRNA- and CRISPR-Cas9-based gene editing screens, corroborated by a metabolite suppression experiment identifies the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) as the target of the broad-spectrum antiviral compound GSK983.

Keywords:

Molecular biology
CRISPR
Antiviral drug
Drug discovery
Metabolite
Pyrimidine metabolism
Small hairpin RNA
Biology
Genome editing
Dihydroorotate dehydrogenase
Virology
Computational biology
Gene knockdown
Biochemistry
Mechanism of action
RNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

125

Citations